Anika Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Anika Therapeutics, Inc. (ANIK) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 0.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-07-29
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2015-03-31 was 54.65%, a 2.57% increase year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2014-09-30 was 53.28%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2014-06-30 was 53.28%, a 7.50% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2014-03-31 was 53.28%, a 7.50% decline year-over-year.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 0.00%, a 100.00% decline from fiscal 2022.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 4.50%, a 12.50% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 0.00% 10-K · filed 2026-03-03 | ||||
| 2025-06-30 | 41.60% 10-Q · filed 2026-07-29 | ||||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-03 | 4.50% 10-K · filed 2025-03-17 | |||
| 2023-12-31 | 0.00% 10-K · filed 2026-03-03 | 4.50% 10-K · filed 2024-03-15 | |||
| 2022-12-31 | 4.50% 10-K · filed 2025-03-17 | ||||
| 2021-12-31 | 4.00% 10-K · filed 2024-03-15 | ||||
| 2020-12-31 | 4.00% 10-K · filed 2023-03-16 | ||||
| 2015-03-31 | 54.65% 10-Q · filed 2016-05-03 | ||||
| 2014-09-30 | 53.28% 10-Q · filed 2014-11-06 | 53.28% 10-Q · filed 2015-11-03 | |||
| 2014-06-30 | 53.28% 10-Q · filed 2014-08-04 | 53.28% 10-Q · filed 2015-08-04 | |||
| 2014-03-31 | 53.28% 10-Q · filed 2015-05-04 | ||||
| 2013-09-30 | 57.60% 10-Q · filed 2014-11-06 | ||||
| 2013-06-30 | 57.60% 10-Q · filed 2014-08-04 | 57.60% 10-Q · filed 2014-08-04 | |||
| 2013-03-31 | 57.60% 10-Q · filed 2014-05-05 | ||||
| 2012-12-31 | 57.60% 10-K · filed 2015-03-13 | ||||
| 2012-09-30 | 57.60% 10-Q · filed 2013-11-05 | 57.60% 10-Q · filed 2012-11-08 | |||
| 2012-06-30 | 57.60% 10-Q · filed 2013-08-06 | ||||
| 2012-03-31 | 57.60% 10-Q · filed 2013-05-06 | ||||
| 2011-12-31 | 57.60% 10-K · filed 2014-03-13 | ||||
| 2011-09-30 | 57.60% 10-Q · filed 2012-11-08 | ||||
| 2011-06-30 | 57.60% 10-Q · filed 2012-08-07 | 57.60% 10-Q · filed 2012-08-07 | |||
| 2010-12-31 | 57.60% 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |